Table 2 Efficacy evaluations at the end-of-treatment visit in ITT population (N = 89)
Glucosamine sulfate and chondroitin sulfate (N = 45) | Cosamin DS® (N = 44) | p value | |
|---|---|---|---|
Analgesic efficacy as evaluated by the Investigator, N (%) | |||
Efficient | 40 (88.9) | 38 (86.4) | 0.717 |
Inefficient | 5 (11.1) | 6 (13.6) | |
Overall efficacy as evaluated by the Investigator, N (%) | |||
Efficient | 34 (75.6) | 35 (79.5) | 0.652 |
Inefficient | 11 (24.4) | 9 (20.5) | |
Reduced pain intensity as evaluated by the subject, VAS (0 to 10 cm), average ± SDa | 4.27 ± 2.83 | 3.58 ± 2.56 | 0.230 |
Efficacy as evaluated by the investigator (based on subjects pain VAS), N (%) | |||
Excellent | 16 (35.6) | 11 (25.0) | 0.358 |
Very good | 10 (22.3) | 12 (27.3) | 0.630 |
Good | 6 (13.3) | 6 (13.6) | > 0.999 |
Average | 8 (17.8) | 9 (20.5) | 0.793 |
Poor | 5 (11.1) | 6 (13.6) | 0.758 |
Clinical efficacy as evaluated by the investigator, N (%) | |||
Excellent | 8 (17.8) | 8 (18.2) | > 0.999 |
Very good | 15 (33.3) | 16 (36.4) | 0.826 |
Good | 11 (24.4) | 11 (25.0) | > 0.999 |
Average | 8 (17.8) | 7 (15.9) | > 0.999 |
Poor | 3 (6.7) | 2 (4.5) | > 0.999 |